We are international
Donate
TEXT SIZE   


Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
Chris L. Pashos PhD
United BioSource Corporation
Lexington, Massachusetts, USA
07.03.12

Abstract No: e18556
This abstract will not be presented at the 2012 ASCO Annual Meeting but has been published in conjunction with the meeting.

Author(s):
Chris L Pashos, Brian G. Durie, Robert M. Rifkin, Rafat Abonour, Rafael Fonseca, Cristina Gasparetto, Jayesh Mehta, Mohit Narang, Jatin J. Shah, Howard R. Terebelo, Sachdev P. Thomas, Kathleen Toomey, Arlene S Swern, Gale Harding, Kristen Sullivan, Thomas Street, Zeba M. Khan; United BioSource Corporation, Lexington, MA; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; US Oncology Research, Denver, CO; Indiana University School of Medicine and the IU/Melvin and Bren Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Scottsdale, AZ; Duke University Medical Center, Durham, NC; Northwestern University Department of Medicine Division of Hematology-Oncology, Chicago, IL; Maryland Oncology Hematology, Owings Mill, MD; University of Texas M. D. Anderson Cancer Center, Houston, TX; Newland Medical Associates, Novi, MI; Illinois Cancer Care, Peoria, IL; Steeplechase Cancer Center, Somerville, NJ; Celgene Corporation, Summit, NJ; United BioSource Corporation, Bethesda, MD; Celgene Corporation, Overland Park, KS

ABSTRACT

Background:
Studies in the United States (US) have identified variation in incidence and survival of multiple myeloma (MM) patients of different races, and noted that MM is the most common hematologic cancer among African Americans. This analysis evaluated whether health-related quality of life (HRQOL) of patients in the US varies by race as they initiate treatment having been newly diagnosed with active, symptomatic MM.

Methods:
Data were collected in Connect MM, a prospective US observational registry begun in September 2009. Data on patient demographics and clinical characteristics were provided by clinicians. HRQOL was reported by patients at enrollment within 2 months of diagnosis. Patients completed the Brief Pain Inventory (BPI), EQ-5D, and Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM). Mean reported scores for BPI, EQ-5D and FACT-MM were analyzed by patient race. Statistical significance was ascertained by ANOVA using SAS 9.1.

Results:
Baseline HRQOL data were reported by 1144 patients (enrolled in 228 centers) of whom 82% were White, 13% Black, and 6% Other race. The cohorts did not differ statistically by ECOG status or by multiple myeloma stage (assessed by either the International Staging System or the Durie and Salmon system). Compared to non-Blacks, Black patients reported less anxiety/depression on the EQ-5D (p=0.030) and better emotional well-being on the FACT-MM (p=0.003). No other statistically significant differences were noted between cohorts on the BPI, other EQ-5D domains (mobility, self care, usual activities, pain/discomfort), or other FACT-MM domains (physical, social/family, functional, and MM-specific considerations).

Conclusions:
Initial results from the Connect MM Registry indicate that baseline HRQOL prior to initiation of treatment may vary by patient race with respect to emotional well-being, and specifically anxiety/depression. These results serve as a baseline reference for future analyses. As patients in the Connect MM Registry proceed through therapy, analyses should be conducted of patients by race, among other characteristics and factors, to determine whether it may be associated with subsequent clinical outcomes and HRQOL over time.


 related articles